Protalix BioTherapeutics (PLX) Change in Acquisitions & Divestments (2021 - 2026)

Protalix BioTherapeutics' Change in Acquisitions & Divestments history runs 4 years deep, the most recent figure standing at $10.0 million for Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments changed N/A year-over-year to $10.0 million; the TTM figure through Mar 2026 stood at $10.0 million (changed N/A YoY), while the FY2025 annual figure was $5.0 million, down 75.51% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $10.0 million, up from $5.0 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $10.0 million in Q1 2026, with the low at $5.0 million in Q4 2022.
• The 3-year median for Change in Acquisitions & Divestments is $5.0 million (2022), against an average of $6.7 million.
• Peak annual rise in Change in Acquisitions & Divestments reached 86.78% in 2022, while the deepest fall reached 86.78% in 2022.
• Protalix BioTherapeutics' Change in Acquisitions & Divestments stood at $5.0 million in 2022, then changed by 0.0% to $5.0 million in 2023, then surged by 100.0% to $10.0 million in 2026.
• Business Quant data shows PLX's Change in Acquisitions & Divestments at $10.0 million in Q1 2026, $5.0 million in Q1 2023, and $5.0 million in Q4 2022.